Phase 3 Peripheral Neuropathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with CIDP (a nerve condition causing weakness and numbness) according to specific international medical guidelines from 2021
- People who have the typical form of CIDP, or one of these specific variants: motor CIDP, multifocal CIDP (also called Lewis-Sumner syndrome), focal CIDP, or distal CIDP
- People whose CIDP symptoms have improved with IVIg (an intravenous immune protein treatment) at some point in the last 5 years
- People who are currently receiving regular IVIg treatment at a standard maintenance dose of at least 0.125 grams per kilogram of body weight per week
- People who still have some ongoing disability and signs of active disease despite current treatment
Who may not be able to join:
- People who have another known autoimmune condition, or any other health condition that could interfere with accurately assessing CIDP symptoms or could put them at unnecessary risk — including nerve damage caused by conditions other than CIDP
- People whose CIDP diagnosis falls into the "possible CIDP" or "sensory CIDP" categories under the 2021 international guidelines
- People who are currently using other long-acting treatments that affect the immune system (confirm with trial site for specific examples)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 857-350-4834
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Reduction of ≥1 point compared with baseline in aINCAT score at week 24
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.